Application of betel pectin in oral ulcer

By using pectin in the genus leaf to improve the expression of ZO-1 and Occludin and regulate mitochondrial functions, the existing oral ulcer treatment has been solved, and effective treatment and prevention of oral ulcers has been achieved, providing a safe, Effective natural plant extract application solutions.

CN118976044APending Publication Date: 2024-11-19HAINAN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411405470.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-10
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing oral ulcer treatment methods are not lasting and have obvious side effects, and there is a lack of a safe and effective application solution for natural plant extracts.

Method used

Using pectin in the leaf of the ceramide as the main component, it regulates mitochondrial function and reduces reactive oxygen levels by increasing the expression levels of the cell tight junction proteins ZO-1 and Occludin, and is used to prepare drugs and medical devices for oral ulcers to enhance oral mucosal barriers. Function.

Benefits of technology

Pectin from the triceps significantly improves the oxidative stress state of oral ulcers, enhances the function of mucosal barrier, and provides a safe and effective new method to treat and prevent oral ulcers. It is suitable for oral ulcers caused by chemotherapy drugs and mucosal damage caused by mucosal ulcers and other causes. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976044A_ABST
    Figure CN118976044A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, and discloses an application of betel pectin in oral ulcers, the betel pectin as a polysaccharide of a natural source is high in safety and small in side effect, and is more suitable for long-term use compared with a traditional chemical medicine; the oral ulcer treatment method based on betel pectin provided by the invention not only has a good treatment effect, but also has relatively high safety and convenience, and provides a new thought and choice for treatment of oral ulcer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medicines, and in particular to application of betel nut pectin in oral ulcers. Background Art

[0002] Oral ulcer, also known as recurrent aphthous ulcer, is a common oral mucosal disease. Its etiology is complex and may be related to genetic, immune, environmental, psychological and other factors. At present, there are many ways to treat oral ulcer, including topical anti-inflammatory and analgesic ointments, oral vitamin and trace element supplements, and the use of immunomodulators. However, these treatments often have certain limitations, such as short-term efficacy and obvious side effects.

[0003] In recent years, with the in-depth study of natural medicines, people have found that many natural plant extracts have good anti-inflammatory, analgesic and healing properties. Therefore, it is of great practical significance to invent a natural plant extract for use in the treatment of oral ulcers. Summary of the invention

[0004] In view of this, the present invention proposes an application of betel nut pectin in oral ulcers, aiming to provide a safer and more effective method for treating oral ulcers with fewer side effects.

[0005] The present invention provides an application of betel nut pectin, which includes at least one of the following:

[0006] A1) Use of betel leaf pectin in the preparation of medicines and medical devices for preventing and treating oral ulcers;

[0007] A2) Application of betel leaf pectin in oral mucosal protection;

[0008] A3) Application of betel nut pectin in oral mucosal protection drugs and medical devices;

[0009] A4) Application of betel leaf pectin in improving oral mucosal barrier function;

[0010] A5) Application of betel leaf pectin in the preparation of drugs and medical devices for improving the barrier function of oral mucosa;

[0011] A6) Application of betel leaf pectin in the treatment of oral mucosal inflammation;

[0012] A7) Use of betel leaf pectin in the preparation of medicines and medical devices for treating oral mucosal inflammation.

[0013] Preferably, betel nut pectin can prevent and treat oral ulcers by increasing the expression levels of cell tight junction proteins ZO-1 and Occludin.

[0014] Preferably, betel nut pectin prevents and treats oral ulcers by regulating mitochondrial function and reducing reactive oxygen species and mitochondrial superoxide levels.

[0015] The present invention also provides a pharmaceutical composition containing betel nut pectin, wherein the pharmaceutical composition comprises an effective amount of betel nut pectin and at least one pharmaceutical carrier, and the pharmaceutical composition is used for treating or preventing oral ulcers.

[0016] Preferably, the dosage form of the pharmaceutical composition includes tablets, capsules, oral liquids, sprays, gels, or ointments.

[0017] The present invention also provides a method for preparing the pharmaceutical composition, comprising:

[0018] The pharmaceutical composition is obtained by uniformly mixing betel nut pectin with a pharmaceutical carrier.

[0019] Preferably, the pharmaceutical dosage form is a tablet, capsule, oral solution, spray, gel, or ointment.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] 1. As a natural polysaccharide, betel leaf pectin has high safety and few side effects. Compared with traditional chemical drugs, it is more suitable for long-term use.

[0022] 2. The present invention not only directly alleviates the damage of oxidative stress to the oral mucosa by regulating the intracellular reactive oxygen level and mitochondrial function, but also enhances the barrier function between cells by increasing the expression of tight junction proteins, thereby protecting the integrity of the oral mucosa in many aspects.

[0023] 3. The experimental results of the present invention show that betel leaf pectin has a significant effect in reversing oxidative stress and improving mitochondrial function, which provides a new idea and method for developing new oral mucosal protective agents.

[0024] 4. The experiments of the present invention also confirmed that betel nut pectin can significantly increase the expression of ZO-1 and Occludin proteins, which provides a new therapeutic target for the treatment of oral mucosal barrier dysfunction caused by chemotherapy drugs.

[0025] 5. The research results of the present invention are not limited to oral ulcers caused by chemotherapy drugs, but may also have therapeutic and preventive effects on oral mucosal injuries caused by other reasons, and have broad application prospects.

[0026] In summary, the betel nut pectin of the present invention has significant therapeutic effects and wide application potential in treating and preventing oral ulcers caused by chemotherapy drugs, and provides a new option for the treatment of related diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Various other advantages and benefits will become apparent to those of ordinary skill in the art by reading the detailed description of the preferred embodiments below. The accompanying drawings are only for the purpose of illustrating the preferred embodiments and are not to be considered as limiting the present invention. Moreover, the same reference symbols are used throughout the accompanying drawings to represent the same components. In the accompanying drawings:

[0028] Figure 1 This is a picture of the improvement of oral ulcers in rats by betel nut pectin in Example 1 of the present invention;

[0029] Figure 2 The betel leaf pectin in Example 4 of the present invention improves the mucosal pathology of rats with oral ulcers;

[0030] Figure 3 The effect of betel nut pectin on the level of reactive oxygen species in HOK cells induced by LPS in Example 2 of the present invention;

[0031] Figure 4 The effect of betel nut pectin on the level of superoxide in HOK cell mitochondria induced by LPS in Example 2 of the present invention;

[0032] Figure 5 The effect of betel nut pectin on the opening degree of mitochondrial permeability transition pore of HOK cells induced by LPS in Example 3 of the present invention;

[0033] Figure 6 The effect of betel nut pectin on LPS-induced mitochondrial membrane potential of HOK cells in Example 3 of the present invention;

[0034] Figure 7 The effect of betel nut pectin in Example 4 of the present invention on the expression level of tight junction protein ZO-1 in HOK cells induced by LPS;

[0035] Figure 8 This is the effect of Piper betel pectin in Example 4 of the present invention on the expression level of tight junction protein Occludin in HOK cells induced by LPS. DETAILED DESCRIPTION

[0036] Exemplary embodiments of the present disclosure will be described in more detail below with reference to the accompanying drawings. Although exemplary embodiments of the present disclosure are shown in the accompanying drawings, it should be understood that the present disclosure can be implemented in various forms and should not be limited by the embodiments described herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present disclosure and to fully convey the scope of the present disclosure to those skilled in the art. It should be noted that, in the absence of conflict, the embodiments of the present invention and the features described in the embodiments can be combined with each other. The present invention will be described in detail below with reference to the accompanying drawings and in combination with the embodiments.

[0037] Example 1 Betel leaf pectin improves 5-fluorouracil-induced oral ulcers in rats

[0038] This example aims to explore the effect of betel nut pectin on oral ulcers in a rat oral ulcer model induced by 5-fluorouracil. The experiment used Sprague-Dawley rats (SD rats), which were provided by Speffort (Beijing) Biotechnology Co., Ltd., and the animal certificate number was NO.110324231106182758. The betel nut pectin used in the experiment was self-extracted, and the extraction method is detailed in the reference: A betel nut pectin and its preparation method and application; 5-fluorouracil was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., with a CAS number of 51-21-8.

[0039] The experimental method is as follows:

[0040] (1) Establishment of oral ulcer model: 27 SPF male Sprague-Dawley rats weighing 180±10g were selected, housed in a standardized environment, and provided with standard feed. After one week of adaptive feeding, the rats were randomly divided into three groups: normal control group (9 rats), 5-fluorouracil model group (9 rats), and betel nut pectin group (9 rats). The rats in the betel nut pectin group were pretreated with 30 mg / kg betel nut pectin for 14 days. Subsequently, the rats in the model group and betel nut pectin group received intraperitoneal injection of 150 mg / kg 5-fluorouracil to establish the model. The day of modeling was taken as the first day of the experiment. 48 hours after modeling, in order to simulate the effect of clinical chronic irritation, an 18-gauge needle was used to gently scratch the cheek pouch mucosa of the rats. The experiment was terminated after 10 days, and all rats were euthanized on the last day of the experiment.

[0041] (2) Morphological study: Oral mucosal samples were fixed in 4% paraformaldehyde, dehydrated, embedded and sliced ​​to prepare paraffin sections. The sections were stained with hematoxylin-eosin (HE), Masson and Sirius Red to quantitatively analyze the deposition of collagen in the submucosal matrix. This part of the pathological section experiment was completed by Wuhan Saiweier Biotechnology Co., Ltd. The experimental results are detailed in Figure 2 .

[0042] The experimental results showed that HE staining showed that the structure of the normal rat oral mucosal epithelium was clear and the spikes were arranged regularly. However, after 5-fluorouracil treatment, the keratin layer atrophied, thinned, and flattened, the spikes shortened or disappeared, and the lamina propria thickened. In contrast, after 5-fluorouracil and betel pectin were treated together, part of the keratin layer recovered and the spikes appeared obviously. SR and Masson staining results showed that the amount of collagen deposition in the buccal mucosa of rats treated with 5-fluorouracil was higher than that in the normal group, while the amount of collagen deposition was reduced after 5-fluorouracil and betel pectin were treated together. It can be seen that betel pectin has the potential to improve 5-fluorouracil-induced oral ulcers in rats.

[0043] Example 2 Piper betel pectin reduces total reactive oxygen species and mitochondrial superoxide levels in human oral epithelial keratinocytes

[0044] There is a causal relationship between the excessive production of reactive oxygen species (ROS) and mitochondrial damage, a process that may eventually lead to cell apoptosis. When the ROS produced in cells exceeds the processing capacity of the antioxidant defense system, oxidative stress (OS) will be induced. Oxidative stress affects a variety of biological processes through various mechanisms, such as promoting inflammatory signal transduction, inducing cell apoptosis, inhibiting autophagy, and damaging mitochondrial function, and is closely related to oral inflammatory diseases.

[0045] Experimental materials include:

[0046] Human oral epithelial keratinocytes (HOK cells, purchased from Shanghai Yingwan Biotechnology Co., Ltd.); total reactive oxygen species DHE probe (purchased from Bio-Tech, catalog number S0033S); mitochondrial superoxide red fluorescent probe (purchased from Yisheng, catalog number 40778ES50); Hoechst 33342 staining solution (purchased from Solebol, catalog number B8040-25mg); oral keratinocyte-specific culture medium (purchased from Welab, catalog number M1004).

[0047] The experimental method is as follows:

[0048] (1) Cell culture and grouping: HOK cells were inoculated in a special culture medium. After the cells proliferated to an appropriate density, they were treated with different culture conditions to form five experimental groups. One group was used as a blank control group with normal culture medium, another group was added with lipopolysaccharide (LPS, concentration of 5 μg / mL) as a model group, and the remaining three groups were added with different concentrations of betel nut pectin (0.3 mg / mL, 1 mg / mL, and 3 mg / mL) on the basis of the model group. Subsequent experiments were carried out after 24 hours of culture.

[0049] (2) Total reactive oxygen species detection: The total reactive oxygen species DHE probe was used to detect the level of intracellular reactive oxygen species. After the DHE probe was diluted with PBS, the cells of each group were incubated at 37°C for 60 minutes in the dark. After washing with PBS, the cell nuclei were counterstained with Hoechst 33342 staining solution for 45 minutes, and then washed with PBS four times, each for 5 minutes, and then the cells were observed using an inverted fluorescence microscope (see Figure 3 ).

[0050] (3) Mitochondrial superoxide detection: Mitochondrial superoxide red fluorescence (MitoSOX Red) probe was used to detect mitochondrial superoxide. The probe was diluted to 5 μM with Hank's balanced salt solution (HBSS), and each group of cells was incubated at 37°C for 30 minutes in the dark. After washing with PBS twice, the cell nuclei were counterstained with Hoechst 33342 solution diluted in HBSS for 45 minutes, washed with PBS four times, 5 minutes each time, and then the cells were observed using an inverted fluorescence microscope (see Figure 4 ).

[0051] The experimental results showed that LPS induced a large amount of ROS in HOK cells and their mitochondria, and after treatment with betel nut pectin, the ROS levels in cells and mitochondria were reduced. This suggests that betel nut pectin can reverse the damage to the oral mucosa caused by oxidative stress by reducing the levels of cellular reactive oxygen and mitochondrial superoxide.

[0052] Example 3 Betel leaf pectin reduces the opening of mitochondrial permeability transition pore and increases mitochondrial membrane potential.

[0053] Experimental materials: including mitochondrial permeability transition pore (MPTP) detection kit and mitochondrial membrane potential detection kit;

[0054] The experimental method is as follows:

[0055] (1) Cell culture and grouping followed the same procedures as in Example 2.

[0056] (2) Mitochondrial permeability transition pore detection: The degree of opening of the mitochondrial permeability transition pore was measured using the MPTP detection kit. The fluorescence quenching solution was a mixture of Calcein AM staining solution and CoCl2. The mixed working solution was applied to the cells for 60 minutes at 37°C, followed by incubation with fresh culture medium for 30 minutes, washing with PBS, and staining with Hoechst 33342 for 45 minutes. Finally, the cells were observed under an inverted fluorescence microscope.

[0057] (3) Mitochondrial membrane potential detection: The mitochondrial membrane potential (MMP) level was determined using a mitochondrial membrane potential assay kit containing TMRE. Cells in the positive control group were pre-treated with CCCP at 37°C for 40 minutes. The probe was diluted with TMRE buffer to a 1× TMRE concentration, and each group of cells was incubated at 37°C for 90 minutes. The cell nuclei were counterstained with Hoechst33342 staining solution at room temperature for 60 minutes, and then the cells were observed under an inverted fluorescence microscope.

[0058] The results showed that in LPS-induced HOK cells, an increase in the openness of MPTP was observed, indicating impaired mitochondrial function. In HOK cells treated with betel nut pectin, the openness of MPTP was reduced (see Figure 5 At the same time, the changes in MPTP were accompanied by changes in mitochondrial membrane potential (MMP). The MMP in the LPS and CCCP groups was significantly reduced, but after treatment with betel nut pectin, the decrease in MMP was significantly reversed (see Figure 6 ). The experimental results revealed that betel leaf pectin can improve mitochondrial function by alleviating the reduction of MMP and the opening of MPTP in HOK cells.

[0059] Example 4 Betel nut pectin significantly increases the expression levels of cell tight junction proteins ZO-1 and Occludin.

[0060] Occludin and ZO-1, as core tight junction proteins, play a vital role in maintaining the tightness between adjacent cells and the barrier function of tight junction proteins.

[0061] Experimental materials: All antibodies used were purchased from Sanying Biotechnology Co., Ltd.; antibody diluents were purchased from Shanghai Bio-Tech Biotechnology Co., Ltd. (including primary antibody diluent P0023A and secondary antibody diluent P0023D); in addition, DAPI ready-to-use staining solution was also prepared.

[0062] The experimental method is as follows:

[0063] The culture and grouping of cells followed the same procedures as in Example 2. For the cell immunofluorescence staining experiment, the cells were washed three times with PBS after the drug culture treatment, and then fixed with 4% paraformaldehyde for 15 minutes and dried at room temperature for 10 minutes. Then, they were washed three times with PBS again, each time for 10 minutes. After blocking with goat serum for 30 minutes at room temperature, the cells were incubated overnight with a primary antibody diluted with 10% goat serum at 4°C. After that, they were washed four times with PBS for 5 minutes each, and incubated with CY3 fluorescently labeled goat anti-rabbit IgG (H+L) for 2 hours at room temperature in the dark. The nuclei were then stained with DAPI staining solution at room temperature for 10 minutes. Finally, the coverslip with cells was moved to a slide with anti-fluorescence attenuation mounting agent, and observed under a fluorescence microscope after sealing.

[0064] The experimental results showed that in the LPS group, the expression levels of ZO-1 protein and Occludin protein decreased, resulting in a weakening of the normal barrier function between cells. However, after betel nut pectin treatment, as the concentration of pectin increased, the expression levels of ZO-1 and Occludin in cells showed an upward trend and were mainly located in the cell membrane, forming a protein barrier (see Figure 7 and 8 ). These results indicate that betel nut pectin can repair the damaged epithelial barrier by regulating the expression levels of ZO-1 and Occludin.

[0065] According to the observations in the above examples, the present invention uses a 5-FU-induced rat chemotherapy oral ulcer model to verify for the first time that betel nut pectin has the following effects: (1) It can improve the atrophy of the keratin layer of the rat oral mucosal epithelium, the shortening or disappearance of the spikes, the thickening of the lamina propria, and the accumulation of collagen; (2) It can reduce the abnormal increase in the levels of total reactive oxygen and mitochondrial superoxide in human oral keratinocytes induced by LPS, reduce the degree of opening of the mitochondrial permeability transition pore, increase the mitochondrial membrane potential, and significantly increase the expression of cell tight junction proteins ZO-1 and Occludin. Through these effects, betel nut pectin can effectively alleviate the damage to the oral mucosal barrier, thereby achieving the treatment and / or prevention of oral ulcers caused by chemotherapy drugs. Therefore, betel nut pectin has the potential to be developed into a health food or drug for the treatment and / or prevention of oral ulcers caused by chemotherapy drugs.

[0066] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the above embodiments, ordinary technicians in the relevant field should understand that the specific implementation methods of the present invention can still be modified or replaced by equivalents. Any modification or equivalent replacement that does not depart from the spirit and scope of the present invention should be covered within the scope of protection of the claims of the present invention.

Claims

1. An application of Piper betel pectin, characterized in that: The application includes at least one of the following: A1) Use of betel leaf pectin in the preparation of medicines and medical devices for preventing and treating oral ulcers; A2) Application of betel leaf pectin in oral mucosal protection; A3) Application of betel nut pectin in oral mucosal protection drugs and medical devices; A4) Application of betel leaf pectin in improving oral mucosal barrier function; A5) Application of betel leaf pectin in the preparation of drugs and medical devices for improving the barrier function of oral mucosa; A6) Application of betel leaf pectin in the treatment of oral mucosal inflammation; A7) Use of betel leaf pectin in the preparation of medicines and medical devices for treating oral mucosal inflammation.

2. The use according to claim 1, characterized in that: Piper betel nut pectin enhances the oral mucosal barrier function by increasing the expression levels of cell tight junction proteins ZO-1 and Occludin; Piper betel pectin prevents and treats oral ulcers by regulating mitochondrial function and reducing reactive oxygen species and mitochondrial superoxide levels.

3. A pharmaceutical composition or oral ulcer gargle containing betel pectin, characterized in that: The pharmaceutical composition or oral ulcer gargle comprises an effective amount of betel nut pectin and at least one pharmaceutical carrier, and the pharmaceutical composition is used for treating or preventing oral ulcer.

4. The pharmaceutical composition according to claim 3, characterized in that The dosage form of the pharmaceutical composition includes a gargle, an oral patch, a tablet, a capsule, an oral solution, a spray, a gel, or an ointment.

5. A method for preparing the pharmaceutical composition according to claim 3, characterized in that: include: The pharmaceutical composition is obtained by uniformly mixing betel nut pectin with a pharmaceutical carrier; The oral ulcer gargle is obtained by uniformly mixing betel leaf pectin with pharmaceutical excipients and purified water.

6. The method according to claim 5, characterized in that The drug dosage form is a gargle, an oral patch, a tablet, a capsule, an oral liquid, a spray, a gel, or an ointment.

Citation Information

Cited By

  • Piper betel pectin extract as well as preparation method and application thereof

    CN121064361A